InterMune
AcquiredInnovative therapies in pulmonology and fibrotic diseases
Palo Alto, United States · Founded 1995
- Headquarters
- Palo Alto, California
- Employees
- 201–500
- Founded
- 1995
- Business Model
- B2B
- Website
- intermune.com
About
InterMune was a biotechnology company focused on research, development, and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). They developed Pirfenidone, marketed as Esbriet® in the EU and Canada. The company was acquired by Roche.
Summary
InterMune is a Biotech company based in Palo Alto, United States, founded in 1995. Investors include Roche and NEA.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Aug 2014
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...